Answers are grounded in this paper and cite their sources.
To the Editor—The report by Abers et al [1] correctly points out that several features of postobstructive community-acquired pneumonia (PO-CAP) distinguish it from bacterial community-acquired pneumonia. These include greater chronicity of disease, greater weight loss, lower white blood cell counts, less sputum production but increased frequency of hemoptysis, fever, cavitary chest lesions, and mortality. Although obstruction was caused by malignancy in all cases, malignancy was first discovered at the time of presentation with pneumonia in 46.7% of cases. The authors emphasize that using modern diagnostic methods, only 10% of patients with PO-CAP had evidence of bacterial infection, and appear to strongly oppose the administration of prolonged antibiotic therapy should the initial regimen fail to produce defervescence. There are several differences between PO-CAP and postobstructive pneumonia seen in patients with established pulmonary neoplasms (both primary and/or metastatic), which represents a more advanced stage of the disease and may require a different approach. Experience at our comprehensive cancer center indicates that approximately 45%–55% of patients with pulmonary neoplasms who develop pneumonia have a postobstructive component, a frequency much higher than the 2%–5% reported for PO-CAP [1, 2]. The majority (>85%) are febrile, have leukocytosis (unless they have chemotherapy-related myelosuppression), and have a productive cough (unless the involved airway is almost completely obstructed). Other common symptoms include dyspnea, pleuritic chest pain, hemoptysis, and weight loss. Microbiologic data are difficult to interpret but generally reveal polymicrobial flora [3, 4]. At our institution, most patients are treated with broad-spectrum antimicrobial regimens directed against healthcare-associated gram-positive organisms (including methicillin-resistant Staphylococcus aureus) and gram-negative bacilli (including the Enterobacteriaceae and Pseudomonas aeruginosa), as these patients frequently have been exposed to hospitals or other healthcare delivery settings for the treatment of their malignancy [4, 5]. Response to therapy is slow and complete defervescence generally does not occur with antimicrobial therapy alone, with repeat/recurrent infections being common. Approximately 10%–15% of patients develop serious complications including lung abscess, empyema, hemorrhage, and fistula formation (bronchopleural or, less frequently, tracheoesophageal). A vicious cycle ensues as these events frequently cause delays in the administration of antineoplastic therapy, which can lead to worsening of the obstruction. Consequently (as also stressed by Abers and colleagues), full attention should be focused on treating the lesion(s) causing obstruction. Several options to accomplish this are available including low- or high-dose-rate brachytherapy, laser therapy, electrocautery, cryotherapy, and the use of airway stents [6, 7]. Unfortunately, despite these measures, progressive, ultimately fatal disease is the norm. Abers and colleagues need to be commended for their interesting, thorough, and timely report. Nevertheless, the entity they describe occurs much earlier during the course of pulmonary malignancy, and indeed, is often the first manifestation of malignancy [1, 2]. In patients with established or progressive disease, the manifestations of postobstructive pneumonia are more varied and severe, responses to antimicrobial therapy are poor, and overall management requires an aggressive multidisciplinary approach. Potential conflict of interest. Author certifies no potential conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
No takes yet. Share an insight, caveat, or question.
Kenneth V. I. Rolston (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: